Alvotech Investor Update: Rosen Law Firm Urges Shareholders to Explore Securities Class Action Claim

NEW YORK — Rosen Law Firm, a global investor rights law firm, has announced it is investigating potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) following allegations that the company may have provided materially misleading business information to the public. The firm states that investors who purchased Alvotech securities may be entitled to compensation through a class action lawsuit without upfront fees under a contingency fee arrangement, and it is preparing legal action to seek recovery of investor losses. The inquiry stems from a November 2, 2025 press release by Alvotech updating the status of its U.S. Biologics License Application (BLA) for AVT05. The FDA issued a complete response letter (CRL) indicating deficiencies that must be resolved before approval, triggering a sharp drop in Alvotech’s stock price — down about 34% on November 3 and nearly 4% on November 4, 2025. Investors interested in participating in the potential class action can submit a form or contact the Rosen Law Firm for more information. The firm highlighted its extensive experience in securities class actions and investor representation. #Alvotech #SecuritiesClassAction #InvestorRights #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM